Most solid organ transplant rejections occur in the one to five years of the transplant. Post-transplant monitoring and early detection of graft rejection are critical and crucial for patients. The old methods of testing graft rejection are invasive, less patient-friendly and unable to detect graft rejection early enough. Late detection of graft rejection causes significant damage to the transplanted organ, resulting in poor quality of life for the patient.
Trunome Liquid Biopsy is a revolutionary non-invasive diagnostic test that enables the early detection and monitoring of chronic diseases through a blood test. Being the first and entirely made-in-India technology platform in Asia, it is protected by patents * “ours” being a US patented technology* and is known for its high effectiveness and accuracy in monitoring organ health.
Trunome-Tx specializes in offering solutions for post-transplant organ health. An innovative diagnostic test called Trunome is a non-invasive method that helps detect early rejection of solid organ transplants through a blood test. This test can effectively monitor the health of transplanted solid organs such as the kidney, liver, heart, lungs, and pancreas. Trunome-Tx also provides specialised care solutions to support post-transplant recovery and long-term health.
